Obesity Canada Cites $27.6B Untreated Cost in Coverage Pivot

Obesity Canada scientific director Dr. Sanjeev Sockalingam is urging governments, insurers and employers to revisit how obesity care is covered following Health Canada's authorization of the first generic semaglutide, pointing to an estimated $27.6 billion in costs from untreated obesity in Canada in 2023 [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/].

The coverage gap behind the call

In a commentary published by Obesity Canada, Sockalingam wrote that fewer than 20 per cent of Canadians with private drug benefit plans have access to Health Canada-approved obesity treatment medications [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/]. He argued that if lower-cost approved options become available, governments, insurers and employers should revisit how obesity care is covered, adding that affordability should not depend on whether someone can find a lower-cost product [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/].

Sockalingam framed the $27.6 billion figure as including both direct healthcare costs and broader productivity losses, citing it as the backdrop against which payers should weigh access decisions [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/].

The regulatory milestone driving the conversation

Health Canada authorized the first generic semaglutide injection on April 28, 2026, making Canada the first G7 country to approve a generic version of semaglutide [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html]. The submission was filed by Dr. Reddy's Laboratories and is a generic version of Ozempic [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html].

Health Canada said it is currently reviewing eight other submissions for generic semaglutide from different companies, and that the department expects to make regulatory decisions on more of these submissions in the coming weeks and months [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html]. The BMJ reported that Canada has become only the second country in the world to approve a generic form of semaglutide, noting that the milestone was made possible after Novo Nordisk did not pay a C$250 annual fee [Source: bmj.com/content/393/bmj-2026-597166].

What Obesity Canada is and isn't saying

Sockalingam emphasized that Obesity Canada does not endorse specific medications, brands or manufacturers, and that its focus is on ensuring people living with obesity have access to comprehensive, evidence-based care, including Health Canada-approved medications when clinically appropriate [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/].

He stressed that pharmacotherapy should only be considered after a full clinical assessment by a healthcare professional competent in evidence-based obesity care, and that treatment decisions should reflect a person's health status, goals, values, preferences, circumstances and obesity-related complications [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/]. The commentary points to the Canadian Adult Obesity Clinical Practice Guidelines, which have been adapted or adopted in countries including Ireland, Chile, Greece and South Africa [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/].

Policy stakes for payers

The Obesity Canada commentary makes a direct comparison to other chronic disease coverage, stating that people living with obesity should not have to pay out of pocket for evidence-based treatment when similar treatment pathways are covered for other chronic conditions, and that Canada would not accept that standard for diabetes, hypertension, arthritis or heart disease [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/].

• First G7 generic semaglutide authorization: April 28, 2026 [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html]
• Other generic semaglutide submissions under Health Canada review: 8 [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html]
• Estimated 2023 untreated-obesity cost in Canada: $27.6 billion [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/]
• Share of Canadians with private drug benefit plans with access to approved obesity medications: under 20 per cent [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/]

For Canadians tracking how the approval flows into pharmacy pricing and benefit design, GLP1Prices.ca maintains a generic semaglutide tracker and an insurance coverage checker. Common questions about how brand products including Wegovy, Rybelsus, Mounjaro and Zepbound are listed and verified are answered in our FAQ.

This article is for informational purposes only and does not constitute medical advice.